Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment

Roehrborn, Claus G.; Kaminetsky, Jed; Auerbach, Stephen M.; Montelongo, Rafael Martínez; Elion-Mboussa, Albert; Viktrup, Lars

doi:10.1111/j.1464-410x.2009.08822.x

Cited by 69 publications

(54 citation statements)

References 23 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, eight studies (from nine publications) [13,14,15,16,17,18,19,20,21] that enrolled 2,913 patients (1,871 tadalafil and 1,042 placebo) were included in the present meta-analysis. The process for the selection of relevant trials was performed as shown in figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…Eight studies [13,14,15,16,17,18,19,20,21] evaluated the change in IPSS, and five studies [13,14,15,19,20] evaluated the change in the IIEF score from baseline to the endpoint for tadalafil. According to the participants who reported having ED at baseline, the two analyses were divided into two subgroups: group BPH (patients with BPH) and group BPH&ED (patients with comorbid BPH and ED).…”

Section: Resultsmentioning

confidence: 99%

“…The change in Q max from baseline was investigated in six studies [13,16,17,18,19,21] including 2,188 patients with BPH. Pooling all four doses (2.5, 5, 10 and 20 mg) showed that there was a non-significant difference in Q max for tadalafil versus placebo (+0.26 ml/s [-0.09 to 0.61], p = 0.14; fig.…”

Section: Resultsmentioning

confidence: 99%

“…4a). However, pooling only the data for tadalafil at a dose of 5 mg (the dose most commonly tested for LUTS/BPH in four studies [17,18,19,21] including 1,147 patients with BPH) showed a significant improvement in Q max (+0.63 ml/s [0.03 to 1.22], p = 0.04; fig. 4b) as compared with placebo.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis

et al. 2013

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Methods: A comprehensive search was done to identify randomized controlled trials comparing the efficacy and safety of tadalafil for LUTS/BPH with placebos. Meta-analytical techniques were applied to evaluate the differences in the study results. Results: Eight studies were identified and analyzed. Compared with placebo, tadalafil was associated with significant improvements in the International Prostate Symptom Score (IPSS) (mean difference = -2.19, p < 0.00001) and the International Index of Erectile Function (IIEF) score (mean difference = +4.66, p < 0.00001), despite the concomitant presence of erectile dysfunction. Significant differences were also observed in the IPSS irritative and obstructive subscores, IPSS quality of life index and BPH impact index. After pooling four doses (2.5, 5, 10 and 20 mg), tadalafil failed to produce a significant outcome in maximal urinary flow rate (Q_max) (mean difference = +0.26 ml/s, p = 0.14), but 5 mg of tadalafil significantly improved Q_max (mean difference = +0.63 ml/s, p = 0.04). No significant difference was detected in the incidence of serious adverse events (risk ratio = 1.00, p = 1.00) after tadalafil treatment. Conclusions: Tadalafil showed good efficacy and safety for improving LUTS and erectile dysfunction in men with BPH, and 5 mg of tadalafil significantly improved Q_max.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Recent studies have demonstrated that PDE5 inhibitors can improve lower urinary tract symptoms (LUTS) and urodynamic parameters [3,4,5]. These indications may be sufficient to convince physicians to prescribe PDE5 inhibitors once daily to patients with erectile dysfunction (ED) with or without concomitant LUTS.…”

Section: Introductionmentioning

confidence: 99%

Impact of the Change in Urinary and Sexual Function on Health-Related Quality of Life after Once Daily Low-Dose Mirodenafil Treatment in Patients with Organic Erectile Dysfunction

Lee

Choe²,

Kim³

et al. 2014

Urol Int

View full text Add to dashboard Cite

Objective: We aimed to evaluate whether changes in urinary and sexual function can influence health-related quality of life. Patients and Methods: Out of 54 recruited patients, 36 were enrolled, and data for 30 participants with erectile dysfunction were available. At baseline and after 1 and 2 months, each participant completed the International Index of Erectile Function (IIEF-15), the International Prostate Symptom Score (IPSS) and the Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36). Uroflowmetry, post-voiding residual volume and the nocturnal penile tumescence (NPT) test were performed at baseline and at the study's conclusion. Results: Compared with baseline, the IPSS, IIEF-15, peak urinary flow rate, NPT parameters and mental component of the SF-36 exhibited significant improvement at the study's conclusion. Among the symptomatic parameters, the changes in the storage and erectile function parameters contributed significantly to the change in the mental component score on the SF-36 (p = 0.007, R² = 0.502). Conclusions: The daily administration of low-dose mirodenafil (50 mg) produced improvements in urinary and erectile function with or without sexual stimulation. Furthermore, this therapy enhanced the mental component of health-related quality of life by improving storage and erectile symptoms.

show abstract

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia

Pattanaik

Mavuduru

Panda

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment

Cited by 69 publications

References 23 publications

Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis

Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis

Impact of the Change in Urinary and Sexual Function on Health-Related Quality of Life after Once Daily Low-Dose Mirodenafil Treatment in Patients with Organic Erectile Dysfunction

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia

Contact Info

Product

Resources

About